Status:

COMPLETED

Endoscopic Nebulizing Device for Surgical Haemostatic-sealant Glubran® 2 Usability Trial in EMR and ESD

Lead Sponsor:

GEM SRL

Conditions:

Gastrointestinal Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aim of this single-center study is to evaluate the feasibility of the technique, usability and safety of the device ENDONEB.

Detailed Description

Single center, prospective, medical device usability and feasibility study. The study will be performed in Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome. According to the recomand...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of superficial neoplastic lesion to be resected by a gastrointestinal endoscopic resection (EMR or ESD)
  • Older than 18 years of age at time of consent;
  • Operable per institution's standards;
  • Signed and dated informed consent form

Exclusion

  • Any clinical conditions precluding the feasibility of gastrointestinal endoscopic resection (ENDONEB could be contraindicated in patients who are suspected of having a gastrointestinal perforation, or are at high risk of gastrointestinal perforation during endoscopic treatment);
  • Pregnant during period of study participation;
  • Allergy history to cyanoacrylate.

Key Trial Info

Start Date :

March 14 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 28 2024

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT06588881

Start Date

March 14 2023

End Date

March 28 2024

Last Update

September 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy, Italy

Endoscopic Nebulizing Device for Surgical Haemostatic-sealant Glubran® 2 Usability Trial in EMR and ESD | DecenTrialz